Target Validation Information
TTD ID	T22583
Target Name	Sodium/glucose cotransporter 2 (SLC5A4)
Type of Target	Clinical trial
Drug Potency against Target	Dapagliflozin	Drug Info	EC50 = 1.12 nM/L	[1]
Action against Disease Model	Dapagliflozin	Drug Info	Dapagliflozin potently and selectively inhibited h uMan SGLT2 versus h uMan SGLT1, the major cotransporter of glucose in the gut, and did not significantly inhibit facilitative glucose transport in h uMan adipocytes. In vivo, dapagliflozin acutely induced renal glucose excretion in normal and diabetic rats, improved glucose tolerance in normal rats, and reduced hyperglycemiain Zucker diabetic fatty (ZDF) rats after single oral doses ranging from 0.1 to 1.0 mg/kg.	[1]
References
REF 1	Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun;57(6):1723-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.